Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the US Patent and Trademark Office (USPTO) has issued US Patent No. 7,795,302 entitled - "Use of Compositions for Treating Rosacea." The patent is part of a portfolio that Quick-Med has licensed from the University of Michigan and extends the growing intellectual property coverage of the company's MultiStat family of compounds.

"This new patent covering methods for treating Rosacea with our MultiStat technology is yet another significant expansion that strengthens the IP estate under our licensing agreement with the University of Michigan," said J. Ladd Greeno, Quick-Med's CEO. "Although an estimated 16 million Americans currently suffer from rosacea, the treatments available today often create unwanted side effects, including skin redness and irritation. MultiStat is shown to promote the maintenance, healing and repair of the inflamed skin, and may be combined with existing medications to deliver more effective, better tolerated treatments."

The patent issued covers methods for treating rosacea with an antimicrobial, a retinoid, and an inhibitor of toll-like receptors in both topical and oral applications. The broad range of antimicrobials to be utilized in combination with the MultiStat family includes tetracycline, erythromycin, azithromycin, clarithromycin, milbemycin, aminoglycoside, penicillin (optimally in combination with a beta-lactamase inhibitor), cephalosporin, fluoroquinolone, streptogramin and sulfanomide.

MultiStat is Quick-Med's family of patented matrix metalloproteinase inhibitors (MMPIs), which have been shown to be highly effective in reducing skin wrinkling and aging. The MultiStat family consists of 10 patented compounds, patented formulae for developing other compounds, numerous use or method patents and other intellectual property involving the use of MMP inhibition techniques in skin therapy. These MMPIs, which have been proven effective in broad-based applications, including improving the appearance of fine lines and wrinkles associated with natural aging or sun-induced premature aging and damage, are marketed to the cosmetics industry as performance ingredients in commercially available anti-aging creams. Quick-Med currently owns or has exclusive licenses for topical uses of MultiStat compounds for cosmetic and military applications.

Rosacea is a chronic skin condition involving inflammation of the cheeks, nose, chin, forehead, or eyelids. It may appear as redness, prominent spider-like blood vessels, swelling, or skin eruptions similar to acne. According to the National Rosacea Society an estimated 16 million Americans currently suffer from rosacea.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the consumer and healthcare markets.